Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain...
PRINCETON, N.J.--(BUSINESS WIRE)--Feb 14, 2024--
In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.
Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.
The FDA has accepted for Priority Review the sNDA for repotrectinib for the treatment of NTRK-positive locally advanced or metastatic solid tumors.